Executive Summary
Upexi Inc (UPXI) delivered a Q3 2025 quarter marked by a contracting top line and continued negative cash generation. Revenue reached $3.16 million, down 78.1% year-over-year and 21.1% quarter-over-quarter, with gross margin remaining solid at approximately 49.3%. However, operating and net losses persisted, with operating income at -$3.59 million and net income at -$3.83 million, translating to an EPS of -$2.87 for the quarter. The EBITDA result stood at -$3.59 million, underscoring ongoing fixed-cost pressure relative to a sharply smaller revenue base.
From a liquidity and balance-sheet perspective, UPXI exhibits material near-term liquidity pressures. The company posted negative cash flow from operations (-$0.78 million) and negative free cash flow, while ending the period with a modest cash balance (~$0.23 million). The current ratio sits at 0.37 and the quick ratio at 0.25, signaling tight short-term liquidity. Leverage remains elevated, with total debt around $6.38 million and a debt-to-equity profile suggesting meaningful fixed obligations against a modest equity base. The reported balance sheet shows a sizable accumulated deficit and a small but positive stockholdersโ equity base (~$1.85 million), with non-cash items (notably other non-cash adjustments) contributing to the narrative but not alleviating cash constraints.
Looking ahead, the absence of explicit full-year guidance in the provided data limits the certainty of a near-term turnaround. A credible path to profitability would require a combination of revenue stabilization or growth, meaningful gross-margin improvement, and tighter cost controls, complemented by working-capital discipline. The stock-trade metrics imply a high-risk, high-uncertainty profile, with UPXI trading at a subdued price-to-sales multiple in the context of a small revenue base and ongoing cash-burn. Investors should monitor topline stabilization, margin trajectory, and any strategic moves (product rationalization, licensing, or partnerships) that could unlock cash flow and improve liquidity.
Key Performance Indicators
QoQ: -21.10% | YoY:-78.12%
QoQ: -47.58% | YoY:-45.92%
QoQ: -234.26% | YoY:27.34%
QoQ: -194.45% | YoY:6.97%
QoQ: -131.45% | YoY:27.71%
Key Insights
Revenue: $3,160,480; YoY -78.12%; QoQ -21.10% | Gross Profit: $1,559,106; Gross Margin 49.33%; YoY -45.92%; QoQ -47.58% | Operating Income: -$3,587,233; Operating Margin -113.50% (approx); YoY +27.34%; QoQ -234.26% | Net Income: -$3,831,660; Net Margin -121.24%; YoY +6.97%; QoQ -194.45% | EPS: -$2.87; EPS YoY +27.71%; QoQ -131.45% | EBITDA: -$3,587,233; EBITDA Margin -113.50% | Cash Flow: Operating Cash Flow -$778,710; Free Cash Flow -$778,710 | Cash Position: Cash and Cash Equivalents $230,392 ...
Financial Highlights
Revenue: $3,160,480; YoY -78.12%; QoQ -21.10% | Gross Profit: $1,559,106; Gross Margin 49.33%; YoY -45.92%; QoQ -47.58% | Operating Income: -$3,587,233; Operating Margin -113.50% (approx); YoY +27.34%; QoQ -234.26% | Net Income: -$3,831,660; Net Margin -121.24%; YoY +6.97%; QoQ -194.45% | EPS: -$2.87; EPS YoY +27.71%; QoQ -131.45% | EBITDA: -$3,587,233; EBITDA Margin -113.50% | Cash Flow: Operating Cash Flow -$778,710; Free Cash Flow -$778,710 | Cash Position: Cash and Cash Equivalents $230,392 | Liquidity: Current Ratio 0.368; Quick Ratio 0.245; Cash Ratio 0.0213 | Leverage: Total Debt $6.38M; Net Debt $6.15M; Debt/Equity 3.45; Interest Coverage 14.64x | Valuation (market): Price-to-Sales 0.88x; P/B 1.51x; P/CF -3.59x; EV/EBITDA negative; Enterprise Value Multiple -2.49 | Shares: Weighted Avg Shares Out 1.336 million
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Revenue |
3.16M |
-78.12% |
-21.10% |
| Gross Profit |
1.56M |
-45.92% |
-47.58% |
| Operating Income |
-3.59M |
27.34% |
-234.26% |
| Net Income |
-3.83M |
6.97% |
-194.45% |
| EPS |
-2.87 |
27.71% |
-131.45% |
Key Financial Ratios
operatingProfitMargin
-113.5%
operatingCashFlowPerShare
$-0.58
freeCashFlowPerShare
$-0.58
Management Commentary
No earnings call transcript data provided in the supplied materials; therefore, key management quotes or thematic highlights from a management Q3 2025 call are not available.
Forward Guidance
No formal guidance was provided in the data snapshot. Given the revenue trajectory (YoY decline) and continued losses, a credible near-term improvement would hinge on: (1) topline stabilization or growth to leverage fixed costs; (2) gross margin expansion through product mix optimization or price/mix optimization; (3) tighter SG&A and operating expenses; and (4) improved working capital management to support cash conversion. Investors should monitor any post-QQ3 updates on strategy execution, potential partnerships or licensing deals, and drivers of consumer demand in U.S. health, wellness, pet, and beauty product segments.